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Relationships between CYP2D6 phenotype, breast cancer and
hot flushes in women at high risk of breast cancer receiving
prophylactic tamoxifen: results from the IBIS-I trial
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BACKGROUND: Several studies have reported discordant results regarding the impact of the CYP2D6 phenotype on both the
effectiveness and the degree of endocrine symptoms associated with tamoxifen. Other studies have suggested that menopausal
symptoms may be a predictive factor to tamoxifen response.
METHODS: We investigated the relationship between the CYP2D6-predicted phenotype and tamoxifen response in a nested case–
control study among women from the International Breast cancer Intervention Study (IBIS-I), which evaluated tamoxifen in the
preventive setting.
RESULTS: In this retrospective analysis of the tamoxifen-treated women in the IBIS-I study, 9 women (16.6%) who developed oestrogen
receptor-positive invasive breast cancer had a 2D6 poor or intermediate metaboliser phenotype compared with 45 (20.6%) controls.
Adjusted matched logistic regression revealed no significant difference between cases and controls for extensive vs intermediate
metaboliser phenotype (OR¼ 0.81 (0.30–2.23), P¼ 0.7) or extensive vs poor metaboliser phenotype (OR¼ 1.02 (0.31–3.32),
P¼ 0.9). Controls in the tamoxifen group with a poor metaboliser phenotype developed nonsignificantly fewer hot flushes compared
with those with an extensive metaboliser phenotype (OR¼ 0.40 (0.12–1.31)), but those with the intermediate phenotype developed
nonsignificantly more hot flushes (OR¼ 1.38 (0.58–3.29)) in an unadjusted analysis.
CONCLUSION: Data from the preventive IBIS-I study did not support an association between the CYP2D6 phenotype and breast
cancer outcome or the development of endocrine symptoms in tamoxifen-treated women.
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Treatment efficacy and treatment-induced endocrine symptoms
are likely to be at least partly related to the underlying host factors,
and specifically to genetic variations involving drug metabolism.
Tamoxifen is metabolised through the cytochrome P450 (CYP)
2D6 pathway to 4-hydroxy-tamoxifen and endoxifen. Both of these
metabolites are believed to be more potent anti-oestrogens than
tamoxifen itself (Mortimer et al, 2008). Reports suggest that
women with specific alterations in the CYP2D6 enzyme, which
correlate with reduced enzyme activity and lower endoxifen levels
(Desta et al, 2004; Borges et al, 2006), may have less benefit from
tamoxifen treatment and fewer hot flushes than women with a
normal enzyme activity (Goetz et al, 2005). Retrospective analyses
from European (Schroth et al, 2007) (HR¼ 2.24 (1.16–4.33),
P¼ 0.02) and Asian (Lim et al, 2007; Kiyotani et al, 2008; Xu et al,
2008) (HR¼ 4.7 (1.1–20.0), P¼ 0.04) studies have found a strong
association between CYP2D6 genotypes and treatment outcomes.
A nested case–control study including 46 women with breast cancer
and 136 controls was conducted within the Italian tamoxifen
prevention trial (Veronesi et al, 2003; Veronesi et al, 2007), and it
was found that women with the low-metabolising CYP2D6 *4/*4
genotype tended to have higher risk of primary breast cancer. The
authors also reported that these women experienced more hot
flushes (Bonanni et al, 2006). However, this was not seen in the
study conducted by Goetz et al (2007). Furthermore, two large
clinical trials in the adjuvant setting (ATAC, BIG 1–98) have
reported no correlation between the CYP2D6 genotype and
recurrence (Rae et al, 2012; Regan et al, 2012).
Vasomotor symptoms, especially hot flushes, are increased for
women taking tamoxifen (Sestak et al, 2006; Cuzick et al, 2007).
Mortimer et al (2008) reported on data from the Women’s Health
Eating and Living study, which showed that women with primary
breast cancer treated with tamoxifen who experienced hot flushes
at baseline had a significantly lower risk of recurrence compared
with women without hot flushes. Similar results were reported with
the ATAC trial where an inverse association between the
occurrence of vasomotor symptoms and breast cancer recurrence
was seen (Cuzick et al, 2008).
Here, we have investigated the association between the CYP2D6
phenotype, breast cancer incidence and hot flushes in
healthy women taking part in the International Breast cancer
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Intervention Study I (IBIS-I) in order to test the hypothesis that
poor metabolisers of tamoxifen are more likely to relapse and have
fewer symptoms.
PATIENTS AND METHODS
The IBIS-I is a randomised, double-blind, placebo-controlled study
of the effects of 5 years of tamoxifen treatment in women at high
risk of developing breast cancer (Cuzick et al, 2002; Cuzick et al,
2007). Detailed study design and baseline characteristics have been
described previously (Cuzick et al, 2002). In short, women aged
35–70 years, having at least a two-fold relative risk of developing
breast cancer, were eligible to join the trial. Women were randomly
allocated to either 5 years of tamoxifen (20 mg per day) or
matching placebo, and were followed up every 6 months during the
5 years of treatment and annually thereafter. Median follow-up for
this analysis was 96 months. The IBIS-I trial was conducted under
the auspices of the UK Coordinating Committee for Cancer
Research (now part of the National Cancer Research Network) and
was approved by the local ethics committee for each participating
centre. The IBIS-I trial is registered as an International Standard
Randomised Controlled Trial, number ISRCTN91879928.
We conducted a case–control study in women allocated to
tamoxifen, in which those women with an oestrogen receptor (ER)-
positive tumour at any follow-up time were included. Women on
tamoxifen with ER-negative tumours were excluded from this
case–control analysis and also did not serve as potential controls.
Purified DNA from whole-blood samples collected at baseline was
analysed using the AmpliChip CYP450 Test at the Roche labora-
tories (Roche Molecular Systems, Inc., Pleasanton, CA, USA), blind
to case–control status and all clinical factors. Each CYP2D6 allele
was assigned to one of four phenotypic categories according to its
associated enzyme function: poor, intermediate, extensive or ultra-
rapid metaboliser. CYP2D6 genotypes were then classified into three
phenotypic categories, ranked from low to high level of enzymatic
function: poor metaboliser, intermediate metaboliser and extensive
metaboliser. Any patient possessing two nonfunctioning alleles was
designated as a poor metaboliser, any patient possessing at least one
decreased function allele with no wild-type allele was designated as
an intermediate metaboliser and any patient with at least one normally
functioning allele was designated as an extensive metaboliser.
All the side effects reported were graded by a clinical observer
(doctor or trained research nurse) at the time of interview. Specific
questions about hot flushes were asked at each 6-month follow-up
visit, but not at baseline, where only details of menopausal
symptoms were recorded. Most hot flushes occurred soon after
women started endocrine treatment (Sestak et al, 2006); therefore,
we used the reporting of these symptoms (all severities) at the first
6-month follow-up visit as our measure of symptom occurrence.
Symptoms reported after 6 months of initiation of the study
therapy were not included in this analysis. Data on concomitant
medications associated with CYP2D6 inhibition were collected
during the 5-year treatment period. The use of strong CYP2D6
inhibitors, namely paroxetine, fluoxetine, quinidine and bupro-
pion, has been evaluated in this analysis. Patients were considered
to have taken inhibitory drugs if prescription/use of the drug was
recorded at any time during their anti-oestrogen treatment period.
The primary objective was to determine the effect of the CYP2D6
phenotype on the development of ER-positive invasive breast
cancer in the tamoxifen arm of the trial. A secondary objective was
to evaluate the effect of the CYP2D6 phenotype on the develop-
ment of endocrine symptoms in the controls. The association
between the CYP2D6 phenotype and breast cancer development or
endocrine symptoms was determined using conditional logistic
regression for case–control sets and logistic regression for
endocrine symptoms. All P-values are two-sided and all confidence
intervals are at the 95% level. All calculations were performed
using STATA (Version 11; StataCorp, College Station, TX, USA).
RESULTS
Cases were women who developed ER-positive (ERþ ) invasive
breast cancer in the tamoxifen arm of the IBIS-I breast cancer
prevention trial. Cases were matched according to personal breast
cancer risk (Tyrer et al, 2004), age and follow-up time with four
controls who also received tamoxifen but did not develop breast
cancer (one case was matched to only three controls). For a total of
54 cases and 215 controls, Cytochrome P450 (CYP) 2D6-predicted
phenotypes were analysed. For four controls, the CYP2D6
phenotype could not be determined, leaving 49 cases with 4
controls and 5 cases with 3 controls for analysis.
CYP2D6 phenotype and risk of breast cancer
Nine (16.6%) women who developed ERþ breast cancer had a
poor or intermediate metaboliser phenotype compared with 45
(18.0%) controls (Table 1). There were no significant differences in
phenotypes between cases and controls. Unadjusted matched
logistic regression revealed no significant difference between cases
and controls for extensive vs intermediate metaboliser phenotype
(OR¼ 0.81 (0.30–2.23), P¼ 0.7) or extensive vs poor metaboliser
phenotype (OR¼ 1.02 (0.31–3.32), P¼ 0.9). No difference was seen
when poor and intermediate metaboliser phenotypes were combined
vs extensive metaboliser (OR¼ 1.07 (0.50–2.31), P¼ 0.9). When the
analysis was adjusted for previous hormone replacement therapy,
smoking status and menopausal status, similar results were seen
as in the unadjusted analysis for poor vs extensive metaboliser
phenotype (OR¼ 0.84 (0.26–2.78), P¼ 0.8) (Table 1).
Only 25 (11.6%) women (5 cases and 20 controls) who had an
extensive metaboliser phenotype used a strong CYP2D6 inhibitor
either at entry or during follow-up. The results remained unchanged
when these women were excluded (data not shown).
CYP2D6 phenotype and risk of hot flushes
We investigated the relationship between the CYP2D6 phenotype
and development of hot flushes at the 6-month visit in controls
receiving tamoxifen (N¼ 211). In all, 50.3% of women with an
extensive metaboliser phenotype developed hot flushes at the
6-month visit, whereas 49.7% did not (P¼ 0.7). For controls with
an intermediate metaboliser phenotype, 58.3% developed a hot
flush compared with 41.7% who did not (P¼ 0.4) (Table 2). Only
four women (28.6%) with a poor metaboliser phenotype developed
hot flushes at the 6-month visit, whereas ten women (71.4%) with
this phenotype did not (P¼ 0.01).
Those with an intermediate metaboliser phenotype had a small
nonsignificant increased risk of developing hot flushes compared
with those with an extensive metaboliser phenotype (OR¼ 1.38
(0.58–3.29)) in an unadjusted analysis. In contrast, those with a
poor metaboliser phenotype developed nonsignificantly fewer hot
flushes at the 6-month visit compared with those with an extensive
metaboliser phenotype (OR¼ 0.40 (0.12–1.31)), and no trend
across phenotype groups was observed (Ptrend¼ 0.3). When the
analysis was adjusted for hormone replacement therapy, smoking
status and menopausal status, similar results were found (Table 2).
Table 1 Distribution of CYP2D6 phenotype (%) according to case–
control status in women receiving tamoxifen
CYP2D6
phenotype
Cases
(N¼ 54)
Controls
(N¼211) OR (95% CI)
OR (95% CI)
adjusted*
Extensive 45 (83.3%) 173 (82.0%) Reference Reference
Intermediate 5 (9.3%) 24 (11.4%) 0.81 (0.30–2.23) 0.88 (0.31–2.47)
Poor 4 (7.4%) 14 (6.6%) 1.02 (0.31–3.32) 0.84 (0.26–2.78)
*Adjusted for hormone replacement therapy, smoking status and menopausal status.
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Very similar results were found if the analysis included both cases
and controls (data not shown).
DISCUSSION
We found no association between the CYP2D6 phenotype and
ERþ breast cancer occurrence in high-risk women receiving
tamoxifen as a preventive agent. These results are in contrast to
those reported by Bonanni et al (2006) in the preventive setting
and Goetz et al (2005, 2007) in the adjuvant treatment setting.
Results similar to that of our study have been reported in the
adjuvant treatment setting by Nowell et al (2005), Wegman et al
(2005), Rae et al (2012), Regan et al (2012), who did not find an
association between CYP2D6 and tamoxifen response/breast
cancer outcome. Despite early suggestions of an impact of the
CYP2D6 genotype and breast cancer (Brauch and Jordan, 2009;
Higgins et al, 2010), no association has been found in these recent
studies.
We found a weak nonsignificant relationship between the
CYP2D6 phenotype and endocrine symptoms. Women with a
CYP2D6 poor metaboliser phenotype developed fewer hot flushes
than women with an extensive metaboliser phenotype. However,
women with the intermediate phenotype had nonsignificantly
more hot flushes. Stronger results were seen in a prospective
cohort study by Henry et al (2009), where women with an
intermediate metaboliser phenotype developed significantly more
hot flushes compared with women with an extensive metaboliser
phenotype. Given the lack of statistical significance of our findings,
the role of CYP2D6 polymorphisms in the development of
endocrine symptoms in women taking tamoxifen remains an open
question.
There are several limitations to this analysis. First, this was a
retrospective unplanned analysis and the study was not designed
to look at the relationship between CYP2D6 phenotype, hot flushes
and breast cancer outcome. Data on hot flushes were not
specifically collected; rather, a set of questions was used to gather
information about several side effects at each follow-up visit.
Furthermore, we do not have information on endocrine symptoms
before study entry, and hence we cannot be certain if hot flushes
reported at the 6-month visit are indeed tamoxifen-induced
symptoms or not. Although the sample size was limited and we
could not rule out a two-fold risk for cancer development, it was
larger than the Bonanni et al, 2006 study, which did find a positive
relationship. For this sample size and phenotype frequencies seen
here in the controls, there would be 74% power to see a two-fold
increase in cancers in the poor and intermediate groups combined
vs the extensive metabolisers (with a two-sided significance level
of 5%).
Although we looked at concomitant medications, the numbers
of women using these drugs were small and they are unlikely to
notably influence these results. Azoulay et al (2011) investigated
the concurrent use of tamoxifen and CYP2D6 inhibitors in a nested
case–control study using data from the UK General Practice
Research Database. They found that the concurrent use was not
associated with an increased risk of breast cancer recurrence, and
furthermore reported that type or strength of the CYP2D6
inhibitor did not affect the results.
In conclusion, data from the IBIS-I study in the preventive
setting could not confirm earlier reports showing an association
between the CYP2D6 phenotype and breast cancer outcome. More
research is needed to understand the factors included in tamoxifen-
induced endocrine symptoms and to investigate the relationship
between endocrine symptoms and breast cancer outcome.
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